TERT and neoplasm: Although our molecular risk stratification cannot be stated to contradict the current approach of releasing small, low-risk lesions as outpatients without additional treatment, the finding of single pT1 tumors with potential, low-abundance mutations suggests that TERT promoter mutational testing might be important regardless of tumor size.